Skip to main content
Premium Trial:

Request an Annual Quote

Nicholas Naclerio, Tom Willis, Kim Blickenstaff, Walter Fredericks, Joseph Smith, Russel Enns, Skip Klein

Premium

ParAllele BioScience tapped Motorola Life Sciences founder Nicholas Naclerio to be president, replacing Tom Willis, who will continue his responsibilities as chief scientific officer.

Naclerio comes to ParAllele from a stint as an independent strategic consultant to “a number of life science companies and venture capital groups.” Previously, Naclerio founded Motorola's Life Science business unit. Naclerio, who will also serve on ParAllele’s board, has served on the boards of Orchid BioScience, Genometrix, Clinical Microsensors, and The SNP Consortium.

Meantime, Mostafa Ronaghi, a co-founder and director of ParAllele, will transition from the board of directors to the scientific advisory board, the firm said.


GeneOhm Sciences has named Kim Blickenstaff to its board of directors. Blickenstaff is co-founder, president, and CEO of diagnostics firm Biosite.


Former LifeCodes head Walter Fredericks has been elected to the board of directors of Matritech, which develops proteomics-based cancer diagnostic products, the Newton, Mass., company said.

Fredericks is the former president and CEO of forensics testing company LifeCodes, which was acquired by Orchid Biosciences in late 2001. He founded Electronic Instruments International, and was CEO of Cistron Biotechnology, and vice president of Becton Dickinson Laboratory Systems.


Cepheid has hired Joseph Smith as vice president and general counsel, and Russel Enns has joined as vice president of regulatory and clinical affairs, quality systems, and reimbursement.

Smith comes to Cepheid from Applied Biosystems, where he was senior vice president of business development. He will have responsibility for all of Cepheid’s legal affairs.

Enns, meantime, comes to Cepheid as a regulatory consultant. Before that Enns was divisional vice president for regulatory affairs at Abbott Labs subsidiary Vysis. He will oversee all corporate regulatory activities worldwide and direct and manage all activities related to establishing clinical trials.


Genaissance Pharmaceuticals has appointed Skip Klein to its board of directors, bringing the number of directors to seven. Klein, 42, is currently managing director of Gauss Capital Advisors, an investment due-diligence and advisory firm that looks for “promising health technology investments,” Genaissance said in a statement.

Filed under

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.